Cited by 406Cancer Immunotherapy and BiomarkersTGF-β signaling in diseasesImmunotherapy and Immune Responses

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Open access

Strauss, Julius, Heery, Christopher R., Schlom, Jeffrey, Madan, Ravi A., Cao, Liang, Kang, Zhigang, Lamping, Elizabeth, Marté, Jennifer L., Donahue, Renee N., Grenga, Italia, Cordes, Lisa, Christensen, Olaf, Mahnke, Lisa, Helwig, Christoph, Gulley, James L.·2018·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-17-2653PMC PMC7985967

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: M7824 (MSB0011359C) is an innovative first-in-class bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD-L1) fused to a TGFβ “trap.” Experimental Design: In the 3+3 dose-escalation component of this phase I study (NCT02517398), eligible patients with advanced solid tumors received M7824 at 1, 3, 10, or 20 mg/kg once every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal; in addition, a cohort received an initial 0.3 mg/kg dose to evaluate pharmacokinetics/pharmacodynamics, followed by 10 mg/kg dosing. The primary objective is to determine the safety and maximum tolerated dose (MTD); secondary objectives include pharmacokinetics, immunogenicity, and best overall response. Results: Nineteen heavily pretreated patients with ECOG 0–1 have received M7824. Grade ≥3 treatment-related adverse events occurred in four patients (skin infection secondary to localized bullous pemphigoid, asymptomatic lipase increase, colitis with associated anemia, and gastroparesis with hypokalemia). The MTD was not reached. M7824 saturated peripheral PD-L1 and sequestered any released plasma TGFβ1, -β2, and -β3 throughout the dosing period at >1 mg/kg. There were signs of efficacy across all dose levels, including one ongoing confirmed complete response (cervical cancer), two durable confirmed partial responses (PR; pancreatic cancer; anal cancer), one near-PR (cervical cancer), and two cases of prolonged stable disease in patients with growing disease at study entry (pancreatic cancer; carcinoid). Conclusions: M7824 has a manageable safety profile in patients with heavily pretreated advanced solid tumors. Early signs of efficacy are encouraging, and multiple expansion cohorts are ongoing in a range of tumors. Clin Cancer Res; 24(6); 1287–95. ©2018 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2653

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725

Show all 35 references

Sorted by citations

Items 101–200 of 406

TGF-β and Cancer Immunotherapy
Maruyama, T., Chen, W., & Shibata, H. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00966 · Cited by 68
Reverting Immune Suppression to Enhance Cancer Immunotherapy
Guerrouahen, B. S., Maccalli, C., Cugno, C., Rutella, S., & Akporiaye, E. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01554 · Cited by 71
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
Kotanides, H., Li, Y. H., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I. V., Surguladze, D., Pennello, A. L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0304 · Cited by 66
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion
Hilmi, M., Nicolle, R., Bousquet, C., & Neuzillet, C. (2020) · Cancers · doi:10.3390/cancers12102969 · Cited by 66
The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target
Yang, Y., Ye, W.-L., Zhang, R., He, X., Wang, J., Liu, Y., Wang, Y., Yang, X., Zhang, Y., & Gan, W.-J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6675208 · Cited by 66
Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases
Shi, N., Wang, Z., Zhu, H., Liu, W., Zhao, M., Jiang, X., Zhao, J., Ren, C., Zhang, Y., & Luo, L. (2022) · Immunologic Research · doi:10.1007/s12026-022-09267-y · Cited by 71
Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy
Tschernia, N. P., & Gulley, J. L. (2022) · BioDrugs · doi:10.1007/s40259-022-00521-1 · Cited by 61
Self-citation
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Li, T., Niu, M., Zhou, J., Wu, K., & Yi, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01562-5 · Cited by 64
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Lamberti, G., Sisi, M., Andrini, E., Palladini, A., Giunchi, F., Lollini, P., Ardizzoni, A., & Gelsomino, F. (2020) · Cancers · doi:10.3390/cancers12113129 · Cited by 66
A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
Fujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 67
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Redman, J. M., Steinberg, S. M., & Gulley, J. L. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0409-8 · Cited by 60
Self-citation
Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
Greco, R., Qu, H., Qu, H., Theilhaber, J., Shapiro, G., Gregory, R. C., Winter, C. G., Malkova, N. V., Sun, F. F., Jaworski, J. A., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1811605 · Cited by 58
TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity
Ali, S., Rehman, M. U., Yatoo, A. M., Arafah, A. M., Khan, A., Rashid, S., Majid, S., Ali, A., & Ali, M. N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175678 · Cited by 60
Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression
Sirica, A. E., Strazzabosco, M., & Cadamuro, M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.10.005 · Cited by 59
Chemotherapy-induced metastasis: molecular mechanisms and clinical therapies
Su, J.-X., Li, S.-J., Zhou, X., Zhang, Z., Yu, Y., Liu, S.-L., & Qi, Q. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01093-8 · Cited by 56
Transforming Growth Factor-β: An Agent of Change in the Tumor Microenvironment
Stuelten, C. H., & Zhang, Y. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.764727 · Cited by 57
Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV– Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets
Williams, E. A., Werth, A. J., Sharaf, R., Montesion, M., Sokol, E. S., Pavlick, D. C., McLaughlin-Drubin, M., Erlich, R., Toma, H., Williams, K. J., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00406 · Cited by 54
miR‐148a‐3p silences the CANX/MHC‐I pathway and impairs CD8 + T cell‐mediated immune attack in colorectal cancer
Zheng, J., Yang, T., Gao, S., Cheng, M., Shao, Y., Xi, Y., Guo, L., Zhang, D., Gao, W., Zhang, G., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202100235r · Cited by 54
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
Jochéms, C., Tritsch, S. R., Pellom, S. T., Su, Z., Soon‐Shiong, P., Wong, H. C., Gulley, J. L., & Schlom, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20680 · Cited by 55
Self-citation
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
Formenti, S. C., Hawtin, R. E., Dixit, N., Evensen, E., Lee, P., Goldberg, J. D., Li, X., Vanpouille-Box, C., Schaue, D., McBride, W. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0633-x · Cited by 53
Clinical immunotherapy in pancreatic cancer
Ye, X., Yu, Y., Zheng, X., & Ma, H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03632-6 · Cited by 54
Immunotherapy in cervix cancer
Attademo, L., Tuninetti, V., Pisano, C., Cecere, S. C., Napoli, M. D., Tambaro, R., Valabrega, G., Musacchio, L., Setola, S. V., Piccirillo, P., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102088 · Cited by 52
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies
Torres, E. T. R., & Emens, L. A. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06423-0 · Cited by 51
Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies
Sheikh, K., Amjad, M., Irfan, M., Anjum, S., Majeed, T., Riaz, M. U., Jassim, A. Y., Sharif, E., & Ibrahim, W. N. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s493643 · Cited by 61
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Seto, T., Sam, D. L., & Pan, M. (2019) · Medical Sciences · doi:10.3390/medsci7020014 · Cited by 52
Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Ungefroren, H. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1636034 · Cited by 53
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
Lan, Y., Yeung, T.-L., Huang, H., Wegener, A. A., Saha, S., Toister‐Achituv, M., Jenkins, M. H., Chiu, L.-Y., Lazorchak, A. S., Tarcic, O., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004122 · Cited by 50
Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy
Lee, H.-J. (2020) · Journal of Cancer Prevention · doi:10.15430/jcp.2020.25.4.213 · Cited by 49
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis
Grenga, I., Donahue, R. N., Gargulak, M. L., Lepone, L. M., Roselli, M., Bilušić, M., & Schlom, J. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.09.027 · Cited by 48
Self-citation
Emerging therapeutic agents for genitourinary cancers
Zarrabi, K. K., Paroya, A., & Wu, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0780-z · Cited by 49
Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ
van den Bijgaart, R. J. E., Schuurmans, F., Fütterer, J. J., Verheij, M., Cornelissen, L. A. M., & Adema, G. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.617365 · Cited by 48
Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment
Li, R., Huang, B. Q., Tian, H., & Sun, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1096717 · Cited by 47
The importance of cancer-associated fibroblasts in targeted therapies and drug resistance in breast cancer
Zheng, J., & Hao, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1333839 · Cited by 49
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., & Yi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196970 · Cited by 52
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
Tan, B. R., Khattak, A., Felip, E., Kelly, K. L., Rich, P., Wang, D., Helwig, C., Dussault, I., Ojalvo, L. S., & Isambert, N. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00809-2 · Cited by 46
Self-citation
Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations
Tabana, Y., Moon, T. C., Siraki, A. G., Elahi, S., & Barakat, K. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1937123 · Cited by 47
Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8+ T cell immunity against solid tumors
Liu, B., Zhu, X., Kong, L., Wang, M., Spanoudis, C. M., Chaturvedi, P., George, V., Jiao, J., You, L., Egan, J. O., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.001 · Cited by 42
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
Harding, J. J., Do, R. K., Yaqubie, A., Cleverly, A., Zhao, Y., Gueorguieva, I., Lahn, M. M. F., Benhadji, K. A., Kelley, R. K., & Abou‐Alfa, G. K. (2021) · Cancer Medicine · doi:10.1002/cam4.3880 · Cited by 44
Proactive and reactive roles of TGF-β in cancer
Kuburich, N. A., Sabapathy, T., Demestichas, B. R., Maddela, J. J., den Hollander, P., & Mani, S. A. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.08.002 · Cited by 43
Transforming of the Tumor Microenvironment: Implications for TGF- β Inhibition in the Context of Immune-Checkpoint Therapy
Löffek, S. (2018) · Journal of Oncology · doi:10.1155/2018/9732939 · Cited by 44
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Kang, Y., Bang, Y., Kondo, S., Chung, H. C., Muro, K., Dussault, I., Helwig, C., Osada, M., & Doi, T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3806 · Cited by 44
Self-citation
Targeting transforming growth factor‐ß signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin
Tewari, D., Priya, A., Bishayee, A., & Bishayee, A. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.795 · Cited by 46
Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells
Cai, J., Cui, Y., Yang, J., & Wang, S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188564 · Cited by 45
Improving function of cytotoxic T‐lymphocytes by transforming growth factor‐β inhibitor in oral squamous cell carcinoma
Kondo, Y., Suzuki, S., Takahara, T., Ono, S., Goto, M., Miyabe, S., Sugita, Y., Ogawa, T., Ito, H., Satou, A., et al. (2021) · Cancer Science · doi:10.1111/cas.15081 · Cited by 43
RETRACTED: Decoding tumor microenvironment: EMT modulation in breast cancer metastasis and therapeutic resistance, and implications of novel immune checkpoint blockers
Yuan, J. X., Li, Y., Zhang, H., Beeraka, N. M., Zhang, D., Wang, Q., Wang, M., Hemanth Vikram, P. R., Sethi, G., & Wang, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117714 · Cited by 47
Retracted
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort
Doi, T., Fujiwara, Y., Koyama, T., Ikeda, M., Helwig, C., Watanabe, M., Vugmeyster, Y., & Kudo, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0249 · Cited by 42
Self-citation
Therapeutic targeting of TGF ‐β in lung cancer
Aftabi, S., Behrooz, A. B., Cordani, M., Rahiman, N., Sadeghdoust, M., Aligolighasemabadi, F., Pistorius, S., Alavizadeh, S. H., Taefehshokr, N., & Ghavami, S. (2024) · FEBS Journal · doi:10.1111/febs.17234 · Cited by 42
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single‐agent checkpoint blockade
Gong, J., Hendifar, A. E., Tuli, R., Chuang, J., Cho, M. T., Chung, V. M., Li, D., & Salgia, R. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0210-9 · Cited by 41
Immunotherapy in prostate cancer: current state and future perspectives
Handa, S., Hans, B., Goel, S., Bashorun, H., Dovey, Z., & Tewari, A. K. (2020) · Therapeutic Advances in Urology · doi:10.1177/1756287220951404 · Cited by 42
Emerging therapeutic targets for patients with advanced prostate cancer
Fred Saad, C., Shore, N. D., Zhang, T., Sharma, S., Cho, H., & Jacobs, I. A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.002 · Cited by 43
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
Lurain, K. A., Ramaswami, R., Yarchoan, R., & Uldrick, T. S. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00525-y · Cited by 42
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
Barlési, F., Isambert, N., Felip, E., Cho, B. C., Lee, D. H., Peguero, J. A., Jérusalem, G., Penel, N., Saâda-Bouzid, E., Garrido, P., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac253 · Cited by 40
Self-citation
68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer
Li, K., Liu, W., Yu, H., Chen, J., Tang, W., Wang, J., Qi, M., Sun, Y., Xu, X., Zhang, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170490 · Cited by 40
Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer
Morris, V. K., Overman, M. J., Lam, M., Parseghian, C. M., Johnson, B., Dasari, A., Raghav, K., Kee, B. K., Huey, R., Wolff, R. A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0194 · Cited by 38
Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy
Vienot, A., Pallandre, J., Renaude, E., Viot, J., Bouard, A., Spehner, L., Kroemer, M., Abdeljaoued, S., van der Woning, B., de Haard, H., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2144669 · Cited by 39
Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review
Khosla, A. A., Jatwani, K., Singh, R., Reddy, A., Jaiyesimi, I. A., & Desai, A. P. (2023) · Pharmaceuticals · doi:10.3390/ph16101461 · Cited by 38
Cancer-associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications
Huang, Z., Chen, J., Zhu, T., Li, J., Ng, H. Y., Zhou, Y., Gu, X., Xu, S., & Jia, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02533-1 · Cited by 49
Exploring optimal sequencing of radiation and immunotherapy combinations
Gunderson, A. J., & Young, K. H. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.07.005 · Cited by 39
Vaccines as an Integral Component of Cancer Immunotherapy
Schlom, J., & Gulley, J. L. (2018) · JAMA · doi:10.1001/jama.2018.9511 · Cited by 38
Self-citation
Targeted exosomes for co-delivery of siFGL1 and siTGF-β1 trigger combined cancer immunotherapy by remodeling immunosuppressive tumor microenvironment
Pei, X., Zhang, X., Zhang, L., Yuan, M., Sun, L., Yu, F., Wang, B., Zhao, J., He, H., & Yang, V. C.-M. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.129774 · Cited by 38
Biological and Clinical Aspects of Metastatic Spinal Tumors
Litak, J., Czyżewski, W., Szymoniuk, M., Sakwa, L., Pasierb, B., Litak, J., Hoffman, Z., Kamieniak, P., & Roliński, J. (2022) · Cancers · doi:10.3390/cancers14194599 · Cited by 39
ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential
Chen, W., Liu, N., Yuan, Y., Zhu, M., Hu, X., Hu, W., Wang, S., Wang, C., Huang, B., & Xing, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1040669 · Cited by 36
Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
Tolcher, A. W., Gordon, M. S., Mahoney, K. M., Seto, A., Zavodovskaya, M., Hsueh, C., Zhai, S., Tarnowski, T. L., Jürgensmeier, J. M., Stinson, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005267 · Cited by 36
Self-citation
Single‐cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Peng, H., Jiang, L., Yuan, J., Wu, X., Chen, N., Liu, D., Liang, Y., Xie, Y., Jia, K., Li, Y., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70054 · Cited by 38
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers
Floudas, C. S., Goswami, M., Donahue, R. N., Pastor, D. M., Redman, J. M., Brownell, I., Turkbey, E. B., Cordes, L. M., Steinberg, S. M., Manu, M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.6998 · Cited by 38
Self-citation
Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer
Adamaki, M., & Zoumpourlis, V. (2021) · Cancers · doi:10.3390/cancers13020173 · Cited by 37
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status
Gameiro, S. R., Strauss, J., Gulley, J. L., & Schlom, J. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221089910 · Cited by 35
Self-citation
Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance
Singh, D., & Siddique, H. R. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10141-y · Cited by 38
Immunotherapy in pancreatic cancer: New hope or mission impossible?
Jiang, J., Zhou, H., Ni, C., Hu, X., Mou, Y., Huang, D., & Yang, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.045 · Cited by 37
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
Spira, A. I., Wertheim, M. S., Kim, E. J.-H., Tan, B. R., Lenz, H., Nikolinakos, P. G., Rich, P. L., Jehl, G., Machl, A. W., Ito, R., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac254 · Cited by 34
Self-citation
Current status and future perspective of immune checkpoint inhibitors in colorectal cancer
Zhou, C., Cheng, X., & Tu, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.023 · Cited by 35
Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications
Zhou, Y., Zhu, G., Lu, X., Zheng, K. I., Wang, Q.-W., Chen, J.-N., Zhang, Q., Yan, F., & Li, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02525-8 · Cited by 33
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
Madan, R. A., Karzai, F. H., Donahue, R. N., Harthy, M. A., Bilušić, M., Rosner, I. L., Singh, H., Arlen, P. M., Theoret, M. R., Marté, J. L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001556 · Cited by 33
Self-citation
Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment
Sethakorn, N., Héninger, E., Sánchez‐de‐Diego, C., Ding, A. B., Yada, R. C., Kerr, S. C., Kosoff, D., Beebe, D. J., & Lang, J. M. (2022) · Cancers · doi:10.3390/cancers14030757 · Cited by 33
Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
Ge, Y., Zhang, Y., Zhao, K., & Zhu, H. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s374672 · Cited by 32
Transforming growth factor‐β signalling in tumour resistance to the anti‐PD ‐(L)1 therapy: Updated
Mortezaee, K., & Majidpoor, J. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17666 · Cited by 32
TGF-β in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer
Singh, S. P., Gouri, V., & Samant, M. (2023) · Medical Oncology · doi:10.1007/s12032-023-02204-5 · Cited by 31
Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert “Cold” Tumors to “Hot” Tumors
Yang, L., Hu, Q., & Huang, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137208 · Cited by 32
Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer
Albrecht, T., Brinkmann, F., Albrecht, M. C., Lonsdorf, A. S., Mehrabi, A., Hoffmann, K., Kulu, Y., Charbel, A., Vogel, M. N., Rupp, C., et al. (2021) · Cancers · doi:10.3390/cancers13071682 · Cited by 31
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience
Merli, M., Accorinti, M., Romagnuolo, M., Marzano, A. V., Zenzo, G. D., Moro, F., Antiga, E., Maglie, R., Cozzani, E., Parodi, A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1208418 · Cited by 30
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses
Kment, J. L., Newsted, D., Young, S., Vermeulen, M., Laight, B. J., Greer, P. A., Lan, Y., & Craig, A. W. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02677-9 · Cited by 31
Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas
Song, L., Weng, J., Li, C.-B., Huo, X., Li, H., Hao, S., Wu, Z., Wang, L., Li, D., & Zhang, J.-T. (2020) · JCI Insight · doi:10.1172/jci.insight.133811 · Cited by 30
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix
Takayanagi, D., Hirose, S., Kuno, I., Asami, Y., Murakami, N., Matsuda, M., Shimada, Y., Sunami, K., Komatsu, M., Hamamoto, R., et al. (2021) · Cancers · doi:10.3390/cancers13061215 · Cited by 29
The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models In Vivo Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ
Yang, Y., Yang, H. H., Tang, B., Wu, A. M. L., Flanders, K. C., Moshkovich, N., Weinberg, D. S., Welsh, M. A., Weng, J., Ochoa, H. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2370 · Cited by 29
Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?
Benkhaled, S., Peters, C., Jullian, N., Arsenijevic, T., Navez, J., Gestel, D. V., Moretti, L., Laethem, J. V., & Bouchart, C. (2023) · Cancers · doi:10.3390/cancers15030768 · Cited by 29
The Use of a Humanized NSG-β2m−/− Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
Morillon, Y. M., Rumfield, C. S., Pellom, S. T., Sabzevari, A., Roller, N., Horn, L. A., Jochéms, C., Palena, C., Greiner, J. W., & Schlom, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00549 · Cited by 29
Self-citation
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma
Khasraw, M., Weller, M., Lorente, D., Kolibaba, K. S., Lee, C. K., Gedye, C. A., de la Fuente, M. I., Vicente, D., Reardon, D. A., Gan, H. K., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab058 · Cited by 29
Self-citation
Research progress in immune checkpoint inhibitors for lung cancer in China
Gan, J., Huang, Y., Fang, W., & Zhang, L. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211029826 · Cited by 27
Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer
Wang, F., Yang, M., Luo, W., & Zhou, Q. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.002 · Cited by 33
Transforming Growth Factor-β1 in Cancer Immunology: Opportunities for Immunotherapy
Villar, V. H., Subotički, T., Đikić, D., Ajtić, O. M., Simón, F., & Santibanez, J. F. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-26163-3_17 · Cited by 32
Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, B., Shen, Z., Hu, S., Zhang, C. H., Zhang, X., Zhang, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202408598 · Cited by 30
FOXC1 plays a crucial role in the growth of pancreatic cancer
Subramani, R., Camacho, F. A., Levin, C. I., Flores, K., Clift, A., Galvez, A., Terres, M., Rivera, S., Kolli, S. N., Dodderer, J. K., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0061-7 · Cited by 29
PD‐L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non‐small cell lung cancer?
Dong, A., Zhao, Y., Li, Z., & Hu, H. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3294 · Cited by 29
TGFβ: Signaling Blockade for Cancer Immunotherapy
Chen, S., Mamaï, O., & Akhurst, R. J. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-103554 · Cited by 29
Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers
Chen, R., Zheng, D., Li, Q., Xu, S., Ye, C., Jiang, Q., Yan, F., Jia, Y., Zhang, X., & Ruan, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215853 · Cited by 28
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
Lin, C., Doi, T., Muro, K., Hou, M., Esaki, T., Hara, H., Chung, H. C., Helwig, C., Dussault, I., Osada, M., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00810-9 · Cited by 28
Self-citation
TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT–Smad3–SHP1 Axis in Lung Adenocarcinoma
Ye, F., Cai, Z., Wang, B., Zeng, C., Xi, Y., Hu, S., Qu, R., Yuan, Z., Yue, J., Tian, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3009 · Cited by 30
Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines
Cubillo, L. T., Gürdal, M., & Zeugolis, D. I. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115317 · Cited by 28
Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives
Lopatnikova, J., & Sennikov, S. V. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679092 · Cited by 31

Authors: Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., Cordes, L., Christensen, O., Mahnke, L., Helwig, C., & Gulley, J. L.
Affiliations: National Institutes of Health (US)
7EMD Serono, Billerica, Massachusetts.
Merck KGaA, Darmstadt (Germany) (DE)
Corresponding author: Gulley, James L.
ORCID: Strauss, Julius
Schlom, Jeffrey
Madan, Ravi A.
Cao, Liang
Kang, Zhigang
Marté, Jennifer L.
Donahue, Renee N.
Cordes, Lisa
Helwig, Christoph
Gulley, James L.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2018-03-14
Volume: 24
Issue: 6
Pages: 1287-1295
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-17-2653
PMC: PMC7985967
OpenAlex: W2781947653
Cited by: 406
References: 35
Citations by year: 2026: 22 · 2025: 29 · 2024: 48 · 2023: 40 · 2022: 81 · 2021: 73 · 2020: 64 · 2019: 26 · 2018: 20
FWCI: 17.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (HHSN261200800001C)
National Cancer Institute (HHSN261200800001E), ZIABC010945)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: bifunctional fusion protein, PD-L1, TGF-β trap, TGF-β1, TGF-beta2, TGF-beta3, advanced solid tumors, maximum tolerated dose, safety, pharmacokinetics, immunogenicity, cervical cancer, pancreatic cancer, anal cancer, carcinoid tumor, dose escalation
MeSH terms: Antineoplastic Agents, Immunological, Adult, Aged, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Transforming Growth Factor beta, Treatment Outcome, Antibodies, Bispecific, Retreatment, Molecular Targeted Therapy, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks